Skip to main content

Table 1 Patient characteristics

From: Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials

   n = 21 Percent
Age Median (range) 57 (29–77) -
Gender Male 14 66.7
Female 7 33.3
ECOG PS 0 19 90.5
1 2 9.5
Primary site Small intestine 10 47.6
Stomach 7 33.3
Others 4 19.0
Site of metastasis Liver 20 95.2
Peritoneum 10 47.6
Lymph node 6 28.6
Others 2 9.5
Number of metastases 0 1 4.8
1–2 15 71.4
≥3 5 23.8
Target lesion Yes 21 100
Previous surgery Yes 14 66.7
Number of previous chemotherapy Median (range) 3 (2–5) -
Previous treatment Imatinib 21 100
Sunitinib 20 95.2
Regorafenib 9 42.9
Interval from first line chemotherapy to starting for phase I trials Median (years) 4.5 (1.4–10.1) -
Number of enrolled phase I trials 1 12 57.1
≥2 9 42.9
Type of phase I trials Targeting agentsa 19 90.5
Cytotoxic agents 1 4.8
Targeting and cytotoxic agents 1 4.8
  1. aTarget: HSP90, BCR-ABL, PDGFR, ALK1, mTOR/p70S6, PI3K, HGF/c-MET, MEK, TEM-1, PTK2, VEGFR+MET, and FGFR